Xenoestrogen concentration in women with endometriosis or leiomyomas: A case-control study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304766 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Victoria Valdes-Devesa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Villaviciosa de Odon, Madrid, Spain. Hauptthemen laut MEDLINE: Endometriosis, Leiomyoma. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Dexeus Mujer.
Abstract (Originalsprache)
Background
Xenoestrogens are synthetic or naturally occurring chemicals capable of altering the endocrine system of humans and animals owing to their molecular similarity to endogenous hormones. There is limited data regarding their effects on women´s health. Chronic exposure to xenoestrogens can promote the development of estrogen-related diseases.
Objectives
To examine xenoestrogen concentration (TEXB-α) differences between women with leiomyomas or endometriosis and control women, and to study the relationship between the clinical and sociodemographic characteristics of these patients and their xenoestrogen levels.
Methods
Prospective case-control study. We selected 221 women who underwent surgery at Quironsalud Madrid University Hospital between 2017 and 2021. The cases included 117 patients: 74 women who underwent surgery for uterine leiomyomas, 21 with endometriosis, and 22 with both pathologies. The control group comprised 104 healthy women who underwent surgical procedures for other reasons. TEXB-α was determined in the omental fat of all patients. Using a questionnaire and reviewing the patients’ medical records, we collected sociodemographic data and other relevant variables.
Results
A significant majority of study participants (68.8%) had detectable levels of xenoestrogens. We found no association between TEXB-α levels in omental fat and the presence of myomas or endometriosis. In the case group, women living or working in Madrid Community exhibited, on average, 3.12 Eeq pM/g higher levels of TEXB-α compared to those working in other areas (p = 0.030). Women who referred to the use of estrogen-containing hormonal contraceptives had, on average, 3.02 Eeq pM/g higher levels of TEXB-α than those who had never used them (p = 0.022).
Conclusions
This study found no association between omental xenoestrogen levels and leiomyomas or endometriosis. However, their presence in most participants and their association with highly polluted areas emphasizes the importance of limiting environmental exposure to these substances. We also identified an association between hormonal contraceptive use and xenoestrogen concentration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Villaviciosa de Odon, Madrid, Spain.
- Department of Obstetrics & Gynecology, Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain.
ORCID-Profile: Victoria Valdes-Devesa, David Sanz-Rosa
Förderung
- Fundación Dexeus Mujer
Zitieren
APA
Valdes-Devesa, V., Sanz-Rosa, D., Thuissard-Vasallo, I. J., Andreu-Vázquez, C., & Sainz de la Cuesta, R. (2024). Xenoestrogen concentration in women with endometriosis or leiomyomas: A case-control study. PLOS ONE. https://doi.org/10.1371/journal.pone.0304766
Vancouver
Valdes-Devesa V, Sanz-Rosa D, Thuissard-Vasallo IJ, Andreu-Vázquez C, Sainz de la Cuesta R. Xenoestrogen concentration in women with endometriosis or leiomyomas: A case-control study. PLOS ONE. 2024. doi:10.1371/journal.pone.0304766
BibTeX
@article{ValdesDevesa2024,
author = {Valdes-Devesa, Victoria and Sanz-Rosa, David and Thuissard-Vasallo, Israel J and Andreu-Vázquez, Cristina and Sainz de la Cuesta, Ricardo},
title = {Xenoestrogen concentration in women with endometriosis or leiomyomas: A case-control study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304766}
}
EUVIMED